Details for New Drug Application (NDA): 214429
The generic ingredient in FEXINIDAZOLE is fexinidazole. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the fexinidazole profile page.
Summary for 214429
| Tradename: | FEXINIDAZOLE |
| Applicant: | Sanofi |
| Ingredient: | fexinidazole |
| Patents: | 0 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 214429
Generic Entry Date for 214429*:
Constraining patent/regulatory exclusivity:
FOR THE TREATMENT OF BOTH THE FIRST-STAGE (HEMOLYMPHATIC) AND SECOND-STAGE (MENINGOENCEPHALITIC) HUMAN AFRICAN TRYPANOSOMIASIS (HAT) DUE TO TRYPANOSOMA BRUCEI GAMBIENSE IN PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 20 KG Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 214429
Suppliers and Packaging for NDA: 214429
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FEXINIDAZOLE | fexinidazole | TABLET;ORAL | 214429 | NDA | Sanofi-Aventis U.S. LLC | 0024-4512 | 0024-4512-14 | 14 TABLET in 1 DOSE PACK (0024-4512-14) |
| FEXINIDAZOLE | fexinidazole | TABLET;ORAL | 214429 | NDA | Sanofi-Aventis U.S. LLC | 0024-4512 | 0024-4512-24 | 24 TABLET in 1 DOSE PACK (0024-4512-24) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 600MG | ||||
| Approval Date: | Jul 16, 2021 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Jul 16, 2028 | ||||||||
| Regulatory Exclusivity Use: | FOR THE TREATMENT OF BOTH THE FIRST-STAGE (HEMOLYMPHATIC) AND SECOND-STAGE (MENINGOENCEPHALITIC) HUMAN AFRICAN TRYPANOSOMIASIS (HAT) DUE TO TRYPANOSOMA BRUCEI GAMBIENSE IN PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 20 KG | ||||||||
| Regulatory Exclusivity Expiration: | Jul 16, 2026 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
Complete Access Available with Subscription
